TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33617910
Drug: Sequential Boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Boost (SEB)
Study: 35927580
Drug: Levodopa (L-DOPA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (L-DOPA; 250 mg)
Study: 36484921
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill combined with home‐based exercise training based on conventional drugs for 12 weeks
Study: 36484921
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs combined with home‐based exercise training for 12 weeks
Study: 36484921
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment only
Study: 33899331
Drug: Near-infrared light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near-infrared light (NIL) therapy combined with meibomian gland expression (MGX)
Study: 33899331
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) therapy combined with meibomian gland expression (MGX)
Study: 35445847
Drug: vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 10 mg every other day + clopidogrel 75 mg daily
Study: 35445847
Drug: vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 10 mg daily + clopidogrel 75 mg daily
Study: 35445847
Drug: clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel 75 mg daily
Study: 35445847
Drug: vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 10 mg every other day
Study: 35445847
Drug: vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 10 mg daily
Study: 34524406
Drug: Sirolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (target serum levels, 4-12 ng/mL)
Study: 33248135
Drug: Immediate laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate laser treatment
Study: 33382385
Drug: Desloratadine citrate
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine citrate disodium (DCD, 8.8 mg/day) + Vitamin D3 nasal drops (1.5x10^6 IU, once/week) for four weeks
Study: 33382385
Drug: Desloratadine citrate
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine citrate disodium (DCD, 8.8 mg/day)
Study: 35022283
Drug: Wet-cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet-cupping therapy (hijama)
Study: 33547784
Drug: Placebo/Atacicept 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/Atacicept 150 mg
Study: 631198356
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering treatment
Study: 631198356
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure lowering treatment
Study: 34488034
Drug: Pharmacist-led systematic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led systematic review of medications for PIM detection using explicit and implicit methods; communication of appropriate therapeutic strategies to physicians.
Study: 34488034
Drug: Pharmacist-led systematic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led systematic review of medications for PIM detection.
Study: 34225463
Drug: Core formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core formulation regimen (test group)
Study: 33236329
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) in combination with conventional induction chemotherapy
Study: 33236329
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) as monotherapy for newly diagnosed AML
Study: 32432489
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) as monotherapy for R/R AML
Study: 36253105
Drug: Levodopa/carbidopa 300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 300/75 mg daily for 80 weeks (early-start group)
Study: 36253105
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 40 weeks followed by levodopa/carbidopa 300/75 mg daily for 40 weeks (delayed-start group)
Study: 36007448
Drug: EWA program
Approvals — FDA: no, EMA: no, PMDA: no
Description: EWA program (two‐year specialized woman only treatment including psychiatric, interpersonal and family concerns)
Study: 36007448
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) in a mixed gender setting
Study: 34085324
Drug: Peripheral muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral muscle strength training (PMT) and respiratory muscle strength training (RMT) associated with conventional physical therapy, one session a day for 5 days.
Study: 34085324
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy, one session a day for 5 days.
Study: 33740734
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² (D75)
Study: 35606823
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care program comprising twelve weekly in-clinic physiotherapy sessions.
Study: 32089338
Drug: Bilateral mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral mental incisive nerve block (MINB) of 1.8 mL of 2% lidocaine with 1:80,000 epinephrine
Study: 32089338
Drug: Unilateral mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral mental incisive nerve block (MINB) of 1.8 mL of 2% lidocaine with 1:80,000 epinephrine
Study: 35666322
Drug: Etidronate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (20 mg/kg for 2 weeks on and 10 weeks off, orally for 12 months)
Study: 32886811
Drug: 200,000 U
Normalized name: nystatin 200,000 UNT Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 U polymyxin B + 40 mg neomycin solution in normal saline (antibiotic)
Study: 35804078
Drug: Reflex locomotion
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflex locomotion therapy (RLT)
Study: 33934208
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation (II) of heparin and alkalinized lidocaine
Study: 36595123
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg orally once daily
Study: 33906954
Drug: Home-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based program with health coaching (8-week intervention, video-guided exercises 6 times a week, weekly health coaching over the telephone)
Study: 33713841
Drug: 4-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month treatment regimen
Study: 33713841
Drug: 6-month standard
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month standard treatment regimen
Study: 34757964
Drug: Various pharmacological
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various pharmacological interventions over the years including anticholinesterases (physostigmine, neostigmine), immunosuppressants (prednisone, azathioprine), intravenous immune globulin, mycophenolate, cyclosporine, tacrolimus, monoclonal antibodies (rituximab, eculizumab)
Study: 34757964
Drug: Immunosuppressant pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressant pharmacological interventions
Study: 34757964
Drug: Newer immunosuppressant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer immunosuppressant drugs (mycophenolate, cyclosporine, tacrolimus)
Study: 34757964
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (rituximab, eculizumab)
Study: 34757964
Drug: Randomized clinical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized clinical trial of drug therapy for myasthenia gravis
Study: 36229663
Drug: Tebentafusp (gp100×CD3),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebentafusp (gp100×CD3), a soluble T cell receptor bispecific
Study: 35968511
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day tandospirone
Study: 35968511
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day tandospirone
Study: 32632491
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg intravenous THC
Study: 32632491
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg intravenous THC
Study: 35251396
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment group
Study: 34891167
Drug: E-cigarette flavors
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-cigarette flavors (green apple, strawberry, chocolate, vanilla, menthol, koolada, peppermint, spearmint, subtle tobacco, full‐flavored tobacco) with nicotine formulations (free-base, salt)
Study: 33394598
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral nutrition (EN), specific dosage and duration not mentioned.
Study: 33394598
Drug: Restrictive dose
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive dose EN into the stomach after initial resuscitation, specific dosage not mentioned.
Study: 33982511
Drug: Objective performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objective performance criteria in post-marketing evaluation of TCM injections
Study: 34601386
Drug: Hypnosis intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnosis intervention (four weekly sessions plus treatment-as-usual)
Study: 34477330
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (480 mg/day)
Study: 33067169
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 800 mg
Study: 35807801
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus acidophilus LA‐5, Lactiplantibacillus plantarum UBLP‐40, Bifidobacterium animalis subsp. lactis BB‐12, Saccharomycesboulardii Unique‐28)
Study: 32340871
Drug: Usual-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual-dose aspirin (325 mg)
Study: 34273468
Drug: Extreme weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Extreme weekly locoregional hypofractionated radiation (HFRT)
Study: 32307005
Drug: Continuing statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing statin treatment at usual dosage
Study: 34733238
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist pretreatment
Study: 34733238
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no GnRH agonist pretreatment)
Study: 33022417
Drug: aPDT (Photodithazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: aPDT (Photodithazine, 200 mg/L, 6 sessions, 3 times a week for 15 days)
Study: 33570770
Drug: Peak CK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak CK within 1st tertile (CK ≤259 U/L; n=1127 patients)
Study: 33570770
Drug: Peak CK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak CK within 2nd tertile (CK 260 to 990 U/L; n=1119 patients)
Study: 33570770
Drug: Peak CK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak CK within 3rd tertile (CK ≥991 U/L; n=1122 patients)
Study: 32453306
Drug: LCPT 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT 2 mg (morning dosing)
Study: 32453306
Drug: LCPT 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT 2 mg (evening dosing)
Study: 32453306
Drug: LCPT 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT 5 mg (after high-calorie meal)
Study: 33579715
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy with predictive low glucose management (SAP + PLGM)
Study: 32317724
Drug: Single-molecule real-time
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-molecule real-time sequencing technology
Study: 34073024
Drug: L-carnitine injection
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine injection three times weekly
Study: 34073024
Drug: L-carnitine injection
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine injection once weekly
Study: 36124697
Drug: Vaccine-boosted
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-boosted
Study: 34219190
Drug: Intravenous hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hypertonic saline (HTS) to achieve and maintain plasma sodium between 145 and 150 mmol/l for 7 days
Study: 33707305
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (SGLT2is)
Study: 32084280
Drug: YAG vitreolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAG vitreolysis treatment
Study: 35793948
Drug: Overminus lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overminus lens therapy
Study: 35793948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no overminus lens therapy)
Study: 32591562
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 600 mg, one tablet a day
Study: 32605614
Drug: stimuli-relevant AATP
Normalized name: Levant cottonseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: stimuli-relevant AATP + treatment as usual (TAU)
Study: 33909188
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus NCDC15 fermented milk with 8 g of Cichorium intybus root powder (LAC) along with basal diet
Study: 33909188
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri BFE7 fermented milk with 8 g of Cichorium intybus root powder (LRC) along with basal diet
Study: 33764198
Drug: Inorganic nitrate
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic nitrate therapy (12 mmol KNO3 capsules)
Study: 33764198
Drug: Placebo (potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (potassium chloride capsules)
Study: 34412699
Drug: Passive educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive educational intervention (daily rounds, journal clubs, morning reports)
Study: 32052995
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care with medication
Study: 35066899
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (RSV) 1000 mg/day for 8 weeks
Study: 36072363
Drug: Gardening sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardening sessions (hour-long, twice weekly for two months) with a group donating vegetables to a food pantry
Study: 36072363
Drug: Gardening sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardening sessions (hour-long, twice weekly for two months) with a group harvesting produce for personal use
Study: 34517135
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg methylprednisone
Study: 32029306
Drug: Half-dose prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose prasugrel (30-mg load followed by 5 mg daily)
Study: 32029306
Drug: Clopidogrel (600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600-mg load followed by 75 mg daily)
Study: 34329567
Drug: Cetagliptin coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetagliptin coadministered with metformin
Study: 34329567
Drug: Metformin coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin coadministered with cetagliptin
Study: 32858791
Drug: Cognitive behavioral‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral‐based group therapy
Study: 32139110
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of legume-based protein
Study: 32139110
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g of legume-based protein
Study: 32139110
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of legume-based protein
Study: 32139110
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of legume-based protein
Study: 35562805
Drug: 5‐methyltetrahydrofolate ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL
Study: 35562805
Drug: 5‐methyltetrahydrofolate ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL in genotype CC
Study: 35562805
Drug: 5‐methyltetrahydrofolate ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL in genotype CT
Study: 35562805
Drug: 5‐methyltetrahydrofolate ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL in genotype TT
Study: 32532275
Drug: UMEC 31.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 31.25 mcg
Study: 32368027
Drug: UMEC 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 62.5 mcg
Study: 35157994
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) plus whole brain radiotherapy (WBRT) (30 Gy in 10 fractions), NTG administered via a transdermal 36 mg patch from Monday to Friday throughout WBRT (10 days)
Study: 34936265
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture combined with suspension training
Study: 33054984
Drug: Audio-visual patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-visual patient information with examples testing a treatment against worms (arm II)
Study: 32497524
Drug: Low-dose vaccine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaccine (3·2 × 10^3 per 0·1 mL)
Study: 32497524
Drug: Medium-dose vaccine
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose vaccine (3·2 × 10^4 per 1 mL)
Study: 32497524
Drug: High-dose vaccine
Normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vaccine (3·2 × 10^5 per 1 mL)
Study: 33760010
Drug: Intrawound vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrawound vancomycin powder (1000 mg)
Study: 34939582
Drug: non-rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-rhGH treatment
Study: 34789638
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement with whey peptides and branched-chain amino acids
Study: 36397087
Drug: Letter sent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letter sent from family doctor to parents informing them of the importance of asthma preventer medication during summer holidays.
Study: 616186557
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (400 mg cefixime)
Study: 616186557
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (400 mg cefixime)
Study: 33496831
Drug: Abaloparatide (ABL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide (ABL), 80 μg
Study: 33496831
Drug: Teriparatide (TPTD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (TPTD), 20 μg
Study: 34596433
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell injection every 3 weeks
Study: 33144246
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy trials
Study: 32842270
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg Q2W, with dose up titration to 150 mg Q2W at week 12 if LDL-C ≥1.81 mmol/L at week 8)
Study: 35976467
Drug: Low-intensity red-light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity red-light (LRL) therapy
Study: 35976467
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of LRL therapy
Study: 32227247
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg immediate-release, twice daily for 36 months)
Study: 35296983
Drug: ISOT (Improving
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISOT (Improving the safety of opioid therapy)
Study: 33382529
Drug: 100 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 × 10^6 CAR+ T-cells (low dose)